The lack of significant difference in the abundance of endothelial cells between meningioma and VS is of interest due to the clinical difference noted in the efficacy of the Vascular Endothelial Growth Factor (VEGF)-targeted monoclonal antibody bevacizumab that is commonly used to treat NF2-SWN VS but ineffective for meningioma [17, 27, 33, 41]. This evidence concerns the gene NF2 and meningioma.